Corporate Finance
Bergs Securities is proud to have acted as certified adviser and financial advisor to Axvik Group in its IPO on Nasdaq First North Growth Market
Bergs Securities acted as sole global coordinator and sole bookrunner in the fully guaranteed SEK 46m rights issue and the SEK 42m private placement of convertible bonds in Abliva
Corporate Finance
Bergs Securities acted as sole global coordinator and sole bookrunner in the fully guaranteed SEK 46m rights issue and the SEK 42m private placement of convertible bonds in Abliva
Abliva develops medicines for the treatment of mitochondrial disease. This congenital, rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.
Related News
Company news
Bergs securities granted additional authorisations by the swedish financial supervisory authority
Company news
Bergs Securities recruits Jonathan Hedin to its Corporate Finance team